Armando E. Giuliano

Armando E. Giuliano, MD is Chief of Surgical Oncology and Co-Director of the Saul and Joyce Brandman Breast Center at Cedars-Sinai Medical Center in Los Angeles. He is one of the most transformative figures in breast and cancer surgery globally, best known for leading the ACOSOG Z0011 trial — arguably the most practice-changing surgical oncology trial of the past 25 years — which demonstrated that axillary lymph node dissection (ALND) could be safely omitted in clinically node-negative breast cancer patients with limited sentinel lymph node (SLN) metastases undergoing breast conservation surgery and whole-breast radiation. Dr. Giuliano pioneered the widespread adoption of sentinel lymph node biopsy in breast cancer with Morton and colleagues in the early 1990s, developing techniques for dual-agent mapping (isosulfan blue dye and technetium-99m colloid) that became the global standard. His initial series and subsequent multi-institutional validations demonstrated that SLN biopsy accurately stages the axilla with minimal morbidity compared with complete ALND. The ACOSOG Z0011 trial (1999–2004), with 10-year follow-up results published in JAMA in 2017, showed no difference in locoregional recurrence, disease-free survival, or overall survival between ALND and SLN biopsy alone in patients with one or two positive SLNs, fundamentally changing axillary management for millions of breast cancer patients annually. Dr. Giuliano's work has been extended to SLN biopsy validation in melanoma, vulvar cancer, and endometrial cancer, establishing it as the staging standard across multiple tumor types.